NV
Novavax, Inc.
NVV1.F · FSX
8.12 € +0.00% (+0.00 €)
1M +19.94%
Market Cap $1.53B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
10.16 €
25.1% upside
Current Price
8.12 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, NVV1.F is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
48 /100
Fair P/S 3.71x
P/E N/A
EV/EBITDA N/A
Growth
0 /100
Declining Rev. growth 11.10%
EPS growth N/A
FCF growth N/A
Profitability
20 /100
Weak Gross margin 77.85%
Net margin 59.93%
Op. margin 53.70%
Quality
8 /100
Poor ROIC 35.62%
ROA 25.92%
Asset turnover 0.43x
Debt
43 /100
Moderate Current ratio 2.33x
Int. coverage -10.63x
Debt/Equity N/A
Stability
3 /100
Unstable Beta 2.42x
Rev. volatility 66.28%
EPS volatility 146.29%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about NVV1.F
Online
Sector
Healthcare
Industry
Biotechnology
CEO
John Charles Jacobs
Employees
749
Headquarters
Gaithersburg
Upcoming events
05 NOV
Earnings
Upcoming earnings report